Close Menu

Trovagene

The collaboration will explore the clinical utility of Trovagene's platform for detecting and monitoring EGFR mutations in lung cancer patients. 

NEW YORK (GenomeWeb) – Trovagene announced Thursday after the close of the market that its third quarter net loss widened as its revenues inched up to $57,000 from $44,000 in Q3 2014.

The Personalized Medicine Coalition announced that Daryl Pritchard will be its new VP of science policy, in charge of promoting the organization's science-related policies and of raising awareness of precision healthcare issues among policymakers, providers, and patients.

Lucigen has hired David Theil as senior vice president and CFO.

NEW YORK (GenomeWeb) – Trovagene said after the close of the market on Thursday that its second quarter revenues were up 14 percent year over year as it sharply narrowed its losses.

NEW YORK (GenomeWeb) – Trovagene has secured a $15 million unrestricted debt facility from Silicon Valley Bank and Oxford Finance, the company said on Tuesday.

NEW YORK (GenomeWeb) — Trovagene has entered into a strategic partnership with two Northwestern University institutions to assess the utility of Trovagene's urine-based cell-free oncogene mutation monitoring technology in clinical practice.

NEW YORK (GenomeWeb) – Trovagene said today it has forged a clinical collaboration with Dana-Farber Cancer Institute to study the use of quantitative urine-based mutation detection for metastatic melanoma.

NEW YORK (GenomeWeb) – Trovagene has assigned all of its miRNA patents to London-based firm GenSignia IP and licensed back the technology, the San Diego-based company disclosed in its Form 10-Q filed with the US Securities and Exchange Commission recently.

NEW YORK (GenomeWeb) – Trovagene reported after the close of the market on Monday a 7 percent decline year over year in revenues for the first quarter, as well as a steep increase in its net loss.

Pages

The US Department of Justice has proposed a rule change to enable DNA to be collected from migrants, the Associated Press reports.

Bernard Fisher, a surgeon who changed how breast cancer is treated, has died at 101, the New York Times reports.

Washington Post columnist writes that she is skeptical about DNA-based diets.

In PNAS this week: recurrent inactivation of DEPDC5 in gastrointestinal stromal tumors, taxonomic reliability of GenBank sequences, and more.